| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA973: Atogepant for preventing migraine |
|
Medicine details |
|
| Medicine name | atogepant (Qulipta®) |
| Formulation | oral formulation |
| Reference number | 5104 |
| Indication | Treatment of chronic migraine - prevention |
| Company | Allergan Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/03/2023 |
| NICE guidance | |